Cellectar Biosciences’ CLR 131 has been granted a Rare Pediatric Disease Designation (RPDD) for the treatment of osteosarcoma, the company announced recently. “Cellectar is pleased to have the opportunity to…

Cellectar Biosciences’ CLR 131 has been granted a Rare Pediatric Disease Designation (RPDD) for the treatment of Ewing’s sarcoma, a rare pediatric cancer, by The U.S. Food and Drug Administration…

Cellectar Biosciences announced today that the U.S. Food and Drug Administration has granted rare pediatric disease designation (RPDD) to its phospholipid drug conjugate, CLR 131, for the treatment of neuroblastoma….

Cellectar Biosciences has been granted orphan drug designation for its therapeutic, CLR 131, by the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for the treatment of neuroblastoma,…